The lead Ambit Biosciences drug candidate, quizartinib, is currently in phase 3 clinical trials among patients with acute myeloid leukemia (AML). San Diego’s Ambit Biosciences will be bought for a total of 315 mill USD.

Ambit Biosciences press release, Sept. 29, 2014